JAK3 and acute lymphoblastic leukemia: JAK1, JAK3, or IL7R mutations predict response to JAK inhibitors, but even T-ALL cases without such mutations could potentially respond to JAK inhibition, most likely due to the presence of other, yet unknown, mechanisms leading to activation of the JAK/STAT pathway.